Olio Labs Says AI Platform Predicts Clinical Trial Outcomes From Animal Studies

Olio Labs announced in a press release that its preclinical in vivo platform uses AI vision models to predict human clinical trial outcomes from animal behavior data.

The platform measures behavioral changes in rodents after drug administration. Those behaviors are passed into models trained on human clinical trial data to predict outcomes such as gastrointestinal adverse events, cardiac toxicity, neuropsychiatric toxicity, and weight loss.

The study says a single 24 hour experiment predicted gastrointestinal side effects, cardiac and neuropsychiatric toxicity, and long term weight loss. The company said its weight loss predictions were 70 percent more accurate than traditional two to three week studies when compared with human weight loss in clinical trials.

Olio Labs said the work is described in the paper titled "A foundational in vivo platform for predicting human health outcomes." The company also said it uses the platform to build combination therapies and is seeking partners to test the technology.